- The FUROSCIX CRL issues relating to the manufacturing facilities are resolvable.
- Bioequivalence has been shown to already-in-use IV Lasix, so we feel comfortable assuming the risk of the unknown CRL issue.
- The commercial opportunity for FUROSCIX has been validated, given that IV Lasix is a commonly used diuretic for patients with heart failure.
- The emphasis from the government on reducing heart failure hospitalization costs bodes well for a new subcutaneous treatment that can be self-administered by patients at home.
- Even factoring in additional financing, the upside is enticing and makes this a high conviction investment idea.
For further details see:
scPharmaceuticals Inc.: The FUROSCIX CRLs Have Created An Excellent Buying Opportunity